---
title: "OSR Holdings Licenses VXM01 Globally to BCM Europe for Up to $815 Million; Share Pledge Secures Milestones"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284813440.md"
description: "OSR Holdings has entered into a Global Exclusive License Agreement with BCM Europe for the development and commercialization of VXM01, a cancer immunotherapy platform, with potential milestone payments of up to $815 million. The agreement includes a royalty pass-through and an option for OSR to sell $15 million of common stock at $10 per share. Additionally, BCM Europe will pledge nearly 10 million OSR shares as collateral for milestone obligations, effective February 15, 2028, after lock-up restrictions expire."
datetime: "2026-04-30T17:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284813440.md)
  - [en](https://longbridge.com/en/news/284813440.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284813440.md)
---

# OSR Holdings Licenses VXM01 Globally to BCM Europe for Up to $815 Million; Share Pledge Secures Milestones

OSR Holdings signed a Global Exclusive License Agreement granting BCM Europe worldwide rights to develop and commercialize VXM01, its oral DNA-based cancer immunotherapy platform. The deal includes up to $815 million in potential milestone payments, a royalty pass-through after investment recovery, and an equity put option allowing OSR to sell up to $15 million of common stock at $10.00 per share within a specified post-effectiveness window. In a related step, BCM Europe and affiliates agreed to pledge 9,974,728 OSR shares as collateral to secure milestone obligations, with the pledge becoming effective on Feb. 15, 2028, after lock-up restrictions expire.

**Agreement 1: OSR Holdings Grants Global VXM01 License to BCM Europe With Up to $815 Million Milestones**

-   **Agreement type**: Global exclusive license agreement for VXM01 immunotherapy platform
-   **Counterparty**: BCM Europe
-   **Signed / Effective**: Apr 29 2026 / Apr 29 2026
-   **Duration / Termination**: N/A
-   **Reason**: Monetize and advance VXM01 via partner-led development

**Agreement 2: BCM Europe and Affiliates Pledge 9.97M OSR Holdings Shares to Secure License Milestones**

-   **Agreement type**: Pledge agreement securing milestone obligations with company shares
-   **Counterparty**: BCM Europe; Bellevue Capital Management; Bellevue Global Life Sciences Investors
-   **Signed / Effective**: Apr 29 2026 / Feb 15 2028
-   **Duration / Termination**: N/A
-   **Reason**: Secure milestone payments under the license

Original SEC Filing: OSR Holdings, Inc. \[ OSRH \] - 8-K - Apr. 30, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [OSRH.US](https://longbridge.com/en/quote/OSRH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [OSRHW.US](https://longbridge.com/en/quote/OSRHW.US.md)

## Related News & Research

- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)